Astellas and Seagen Receive Positive CHMP Opinion for PADCEV

/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that the...

Related Keywords

Norway , Iceland , Tokyo , Japan , United States , California , Liechtenstein , Canada , Washington , Switzerland , Seattle , American , Kenji Yasukawa , Ahsan Arozullah , Enfortumab Vedotin , American Society Of Clinical Oncology , Astellas Pharma Us Inc , European Commission , Seagen Inc , Nasdaq , Exchange Commission , Astellas Pharma Inc , Most Common Adverse Reactions Including Laboratory Abnormalities , European Union , European Medicines Agency , European Union Member States , Committee For Medicinal Products Human Use , Astellas Pharma , Medicinal Products , Human Use , Vice President , Medical Sciences Oncology , New England Journal , Important Safety , Toxic Epidermal Necrolysis , Common Adverse Reactions , Including Laboratory Abnormalities , Dualp Gp , Prescribing Information , Focus Area Approach , Quarterly Report , Accessed December , Bladder Cancer Factsheet , Previously Treated Advanced Urothelial , Vedotin Antibody Drug Conjugate Targeting , Highly Potent Therapeutic Agent , Multiple Preclinical Cancer , Cancer Res , Pharmaceuticals , Medical Pharmaceuticals , Health Care Amp Hospitals , Clinical Trials Amp Medical Discoveries ,